About Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited is a public company incorporated on February 14 1995. Its registered office at Block E, Sector-18, Rohini, New Delhi 110085 . The company traces its roots to 1949 and today provides a comprehensive menu of 5,000+ diagnostic tests and panels, including specialised and genomic testing, through a nationwide network of laboratories and service centres. 

Its portfolio spans biochemistry, haematology, histopathology, microbiology, immunology, virology, cytology, electrophoresis, immuno-chemistry, and radiology investigations, alongside branded offerings such as Genevolve (genomics), L-CoRD (reproductive diagnostics) and L-ACE (autoimmune disorders), plus AI-enabled diagnostics and tech-enabled sample tracking  . Dr. Lal PathLabs operates across India with international subsidiaries and labs in Nepal and Bangladesh, reflecting a Pan-India footprint with select overseas presence.

Dr. Lal PathLabs Limited Key Milestones 

Key milestones include establishing Asia’s largest National Reference Lab in Delhi (2010), becoming the first Indian healthcare company to list via IPO (2015), launching the first COVID RT-PCR testing network in India’s private sector (2020), and subsequent expansions such as reference labs in Mumbai and Bengaluru and acquisitions like Suburban Diagnostics (2021) .

Dr. Lal PathLabs Limited’s Business Segments

• Market segments (FY25 revenue mix): B2C 74%; B2B 26% .
• Geography (FY25 mix): International operations contributed less than 2% of total revenue; the balance was domestic .
• Within India (FY25 region-wise revenue contribution): Delhi NCR 31.08%; UP & Uttarakhand 18.62%; Rest of North 13.20%; East 14.55%; West 14.62%; South 5.62%; Others 2.31%.

Dr. Lal PathLabs Limited Key Management 

• (Hony) Brig. Dr. Arvind Lal – Executive Chairman.
• Shankha Banerjee – Chief Executive Officer (w.e.f. May 21, 2024) .
• Ved Prakash Goel – Chief Financial Officer & CEO – International Business.
• Vinay Gujral – Company Secretary & Compliance Officer.

Latest Updates on Dr. Lal PathLabs Limited

• Network expansion: In FY25, the company opened 18 new labs and added 800+ collection centres to deepen reach, particularly into Tier 3 and Tier 4 locations, while continuing investments in metro and tiered city infrastructure  .
• Portfolio enhancement: Nearly 80 high-end tests were added during the year, strengthening specialised and complex testing capabilities; the SwasthFit preventive health packages contributed 24% of sales in FY25  .
• Digital and AI: The company continued deploying AI across cancer diagnostics, autoimmunity, antibiotic sensitivity, haematology and other departments, as part of a broader digital transformation strategy covering medical technology, AI & automation, and infra upgrades  .
• Operating scale: As of FY25, the network comprised 298 labs, 6,607 patient service centres and 12,365 pick-up points, serving 28.8 million patients and processing 85.6 million samples; 40 labs were NABL-accredited and 2 were CAP-accredited .
• Corporate actions: Suburban Diagnostics’ business undertaking was consolidated into Dr. Lal PathLabs on a going-concern basis effective March 18, 2025, following a voluntary liquidation process approved in February 2025.